This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

IASLC LALCA, Mexico City, Mexico,1 7-19 October 2019

Overall survival in patients with EGFR mutation-positive NSCLC receiving sequential afatinib and osimertinib: updated analysis of the GioTag study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A. Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Cufer

lalca_2019_giotag_update_poster.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

This video abstract summarizes updated results, including overall survival data, from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations.

6.42

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

Rate this

FOR HEALTHCARE PROFESSIONALS ONLY

image